Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 mRNA lipid nanoparticles
- Development stage
- Unknown
- Lead developer
- Third Military Medical University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Intravenous
01
Overview
Anti-CD19 mRNA lipid nanoparticles (LNPs) represent an innovative therapeutic platform designed to deliver messenger RNA encoding anti-CD19 antibodies or chimeric antigen receptors (CARs) directly into cells in vivo. By encapsulating the mRNA in lipid nanoparticles, the genetic material is protected from enzymatic degradation and efficiently delivered to target cells, where it is translated to produce functional anti-CD19 proteins. This approach is being investigated for the transient depletion of CD19-positive B cells and plasma cells, offering a promising strategy for resetting the humoral immune system in autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), as well as for treating B-cell malignancies without the need for ex vivo cell manipulation.
- Other names
- CD19-targeting mRNab-LNPsCD-19-targeting mRNab-LNPsCD 19-targeting mRNab-LNPslipid nanoparticle-encapsulated mRNA-targeting CD19mRNab-LNPs
02
Targets
Beyond the preview
Go deeper on anti-CD19 mRNA lipid nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 mRNA lipid nanoparticles.